Ozmosi | Vornorexant Drug Profile
Drug Profile
Using advanced filters...

Vornorexant

Pronounced as: vor-noh-REX-ant

Alternative Names: Vornorexant, ts-142, ts 142, ts142
Clinical Status: Active
Latest Update: 2025-02-28
Latest Update Note: Clinical Trial Update

Product Description

Taisho R&D is developing ts-142, an Oral DORA Antagonist for insomnia

Mechanisms of Action: DORA Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Taisho
Company Location:
Company Founding Year: 1912
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vornorexant

Countries in Clinic: Japan

Active Clinical Trial Count: 5

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Insomnia

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05461352

TS142-302

P3

Completed

Insomnia

2024-03-07

3%

2025-03-01

Primary Endpoints|Treatments

jRCT2071230009

jRCT2071230009

P1

Recruiting

Insomnia

2023-09-30

jRCT2031220463

jRCT2031220463

P1

Recruiting

Insomnia

1970-01-01

jRCT2031220208

jRCT2031220208

P3

Active, not recruiting

Insomnia

2024-05-15

jRCT2031220209

jRCT2031220209

P3

Recruiting

Insomnia

2024-01-15

Recent News Events

Date

Type

Title